医药品·生物科技交易的权利金费率(2010年～2025年)

"製药和生物技术交易中的特许权使用费率" 报告为您提供数千笔交易的真实信息，包括许可技术、特许权使用费率、许可费、预付款和里程碑付款。

本报告详细介绍了製药、生物技术和诊断领域最新公布的合作项目，并揭露了特许权使用费率。本报告涵盖了2010年至2025年间超过1,700个合作项目，并揭露了特许权使用费率。

本报告概述了公司如何以及为何签订在化合物或技术商业化后支付特许权使用费的合作协议。

了解潜在合作伙伴协商的交易条款的弹性，可以为谈判过程提供重要的参考，从而了解谈判期间的预期结果。虽然许多中小企业会寻求详细的付款条款，但在付款方式方面，细节决定成败。

本报告全面列出了自2010年以来宣布的1,700多笔合作交易，这些交易披露了 "当前协议" 交易和合作资料库中记录的量化特许权使用费率。每笔交易记录和特许权使用费率揭露都透过交易线上副本的连结进行详细说明，其中包括公司及其合作伙伴向美国证券交易委员会提交的实际合约文件（如有）。

本报告的第一章探讨了自2010年以来製药和生物技术领域的特许权使用费率趋势。第一章对报告进行了介绍，第二章概述了自2010年以来製药和生物技术领域的特许权使用费率趋势。

第三章更深入地探讨了特许权使用费率条款的结构以及它们如何与合作协议的其他财务条款相协调。

第四章深入分析了主动揭露特许权使用费率的公司以及特许权使用费率最高的交易。

第五章全面详细地介绍了自2010年以来披露特许权使用费率的交易，并提供合约文件。合约文件详细介绍了双方就特许权使用费率达成的实际条款和条件。

报告还提供了一个全面的交易目录，列出了自2010年以来所有揭露特许权使用费率的交易。交易按公司名称、签约时的开发阶段、治疗领域和技术类型进行分类。每个交易标题都提供了一个指向交易记录线上版本的超链接，其中包括实际的合约文件。

报告还包含大量图表，展示了自2010年以来製药和生物技术交易中特许权使用费率的趋势。

总之，本报告为交易撮合者提供了他们需要了解的有关製药和生物技术领域特许权使用费率的所有资讯。

主要优势

製药和生技专利费率有以下优点：

• 了解自2010年以来的专利费率趋势
• 透过实际案例研究分析专利费率条款结构
• 取得揭露专利费率的合作和授权协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 首付款、里程碑付款、专利费
• 依公司A-Z、治疗重点及技术类型分类的交易目录
• 取得合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

范围

• 本报告旨在详细了解世界领先生命科学公司达成的交易的专利费率趋势和结构。

製药和生技交易中的特许权使用费率包括：

• 2010 年以来生物製药业的特许权使用费率趋势
• 特许权使用费率条款的结构分析
• 包含特许权使用费率揭露的实际授权协议案例研究
• 2010 年以来包含特许权使用费率揭露的许可协议综合列表
• 存取包含特许权使用费率揭露的授权协议文件
• 2010 年以来按特许权使用费率金额划分的主要许可协议
• 2010 年以来最活跃的特许权使用费率揭露

製药和生物技术交易中的特许权使用费率列出了可用的交易和协议。

• 公司 A-Z
• 标题金额
• 治疗领域
• 技术类型
• 每个交易标题都透过网页连结连结到实际交易记录的线上版本。
• "製药和生物技术特许权使用费率报告" 提供对许可协议现有合约文件的全面存取。

分析实际协议可以让您评估：

• 授予的具体特许权使用费率是多少？
• 每个合作公司实际获得的授权是多少？
• 授予了哪些独家权利？
• 协议的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期限是怎样的？
• 协议的关键条款是如何定义的？
• 智慧财产权的处理和所有权是什么？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密权和揭露权？
• 如何处理纠纷？如何解决？
• 合约在什么情况下可以终止？
• 如果所有权改变会发生什么事？
• 双方约定了哪些再授权或分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款似乎因合作伙伴或交易类型而异？
• 公司主张哪一契约法管辖权？

目录

摘要整理

第1章 简介

• 什么是特许权使用费？
• 特许权使用费率历史
• 製药和生物技术领域的特许权使用费率
• 特许权使用费率与收益分成
• 报告概述

第二章：製药和生物技术特许权使用费率概述

• 2010 年至 2025 年特许权使用费率趋势
• 收益分成计算方法
• 近期文献综述
• 未来特许权使用费率

第三章：製药和生技交易中的特许权使用费率条款

• 合作协议结构
• 典型的特许权使用费率条款结构
• 特许权使用费率条款范例

第四章：主动揭露特许权使用费率的公司

• 最主动揭露特许权使用费率的公司费率

第5章 特许权比率契约名录

• 找出交易协议中的特许费率，深入了解
• 交易目录
• 交易目录 - 交易特许费率 - 按公司 (AZ)
• 交易目录 - 交易特许费率 - 按治疗领域
• 交易目录 - 交易特许费率 - 按协议签订时的开发阶段
• 交易目录 - 交易特许费率 - 按技术类型
• 特许费率参考
• 特许费率协议范例
• 关于研究公司
• 当前合作伙伴关係
• 当前协议
• 目前合作伙伴的最新报告标题

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on thousands of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of 1,700+ partnering deals disclosing royalty rates from 2010 to 2025.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of 1,700+ partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

• Understand royalty rate trends since 2010
• Analysis of the structure of royalty clauses with real life case studies
• Browse collaboration and licensing deals which reveal a royalty rate
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
• The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

• 1.1. What are royalties?
• 1.2. History of royalty rates
• 1.3. Royalties in pharmaceuticals and biotechnology
• 1.4. Royalties versus revenue share
• 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

• 2.1. Trends in royalty rates 2010 - 2025
• 2.2. How do revenue shares figure?
• 2.3. A review of recent literature
• 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

• 3.1. Partnering agreement structure
• 3.2. Structure of a typical royalty clause
• 3.3. Example royalty clauses
  • 3.3.1. Case study 1
  • 3.3.2. Case study 2
  • 3.3.3. Case study 3
  • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

• 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight
• Deal Directory
• Deal Directory - Royalty rates in deals - by company A-Z
• Deal Directory - Royalty rates in deals - by therapy area
• Deal Directory - Royalty rates in deals - by stage of development at signing
• Deal Directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2025
• Figure 2: Components of the partnering deal structure
• Figure 3: Components of the partnering royalty clause
• Figure 4: Most active companies disclosing royalty rate 2010 - 2025
• Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies